| TheStreet.com | Biotech Movers: Fate Shares Spike After Cancer Studies Progress TheStreet.com ... coverage with a Buy rating and $5 price target. Maxim pointed to key advantages of its IDXG's thyroid diagnostics platform compared to market leader Veracyte Inc. (VCYT) . Maxim predicted IDXG's thyroid assay revenue could reach $50 million by 2022. and more » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uFOx0D
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,